DS9 Document EFTA00282981

1101: M.D. fax: FACSIMILE TRANSMISSION Date: \Clili,, /961e' A) PLEASE DELIVER ATTACHED MESSAGE TO: Z - e---c-Ciq'el e FAX #: TEL #: Regarding: Number of pages (Including cover Remarks: page): L aL-rC 4£91886Z1Z1 14-1sti Lt:SO 9tOZ PROT0 115.0 allev ',VT. bwri label Na RAW <AN raftl•st••••••••• rwrxr • h. v j • I ..r.•• Ft PA army, e. A . wariot* lMaimis 3 ,•24 tam:ha. Bea Liked med te.to d fie bzr Anorat .r.A.M.O. : ary miler g fir ;WAX Do. , PROT1 M9 09 2016 0a37RI Harry Fitt' 12129881630 page 3 Q yavv?-7yryy ki-vvn ineyb vs>f PROT2 BioReference LABORATORIES FINAL REPORT 0 0 L riscw, HARRY HARRY FISCH. M.D. New York, MY 10028 51 P: EPSTEIN, ]ErrRre D08:01/2%/1953 Age:63 Y Sex:PI ,Address: E 71ST STREET -.NEW YORK ( NY 5 A M Specimen ID: 105819158 Date Of Report:07/23/2016 Date Collected:07/20/2016 Time Collected: 08:52 Date Received: 07/20/2016 Time Received: 23:20 North America Eastern Time Clinical Abnormalities !Wirnary: Nal no a-vair all etncere lemAs refra ve .esuss rey VI nrie steams sags fiease Mont eine moon ) Creatinine 0.62 10 muV/Creat Ratio Cholesterol 210 HI Triglycerides HDL as % of 13 Chol/HDL Ratip Cholesterol MCHC 35.2 MI Hemoglobin Alc 5.9 HI 33.9 HI ALT 42 HI 950 HI HDL CHOL., DIRECT 28 10 7.5 NON PAST1h; CHEMISTRY ' teltrAniMa nakr- -ka42. - I" aa:::::::=ggigirjliagagMtapkalla:tr.:121ACI: i.:-.1 Total Protein 7.0 5.9.8.4 8/dl 6.7 ,01/27/2016 Albumin 4.7 3.5-5.2 g/dL 4.2 01/27/2016 Globulin 2.3 1.7-3.7 g/dL 2.5 01/27/2016 A/G Ratio 2.0 1.1-2.9 1.7 01/27/2016 Glucose 93 70-99 mg/c11. 99 01/27/2016 Sodium 140 135-147 asol/L 141 01/27/2016 Potassium 4.6 3.5-5.5 msol/L 4.2 01/27/2016 Chloride 97 96-108 msol/L 102 01/27/2016 CO2 24 22-29 msol/L 26 01/27/2016 BUN 21 8-23 mg/cll. 22 01/27/2016 Creatinine 9.62 LO 0.80-1.30 mg/dL 1.11 01/27/2016 e-GFR 106 >or460 ml./min 70 01/27/2016 e-GFR, African American 123 >or-60 mL/min 81 01/27/2016 sun/crest Ratio 33.9 HI 10.0-28.0 19.8 01/27/2016 Calcium 9.8 8.6.10.4 mg/dL 9.8 01/27/1010 Uric Acid 7.4 3.4-8.5 mg/dL 7.5 01/27/2016 Iron 96 45-168 ug/dL 75 01/27/2016 8111rubin, Total 0.6 <1.2 mg/dL 0.5 01/27/2016 LID 206 135-225 U/L 171 01/27/2016 Alk Phos 70 40-156 U/L 43 01/27/2016 AST 32 <40 U/L 29 01/57/2016 Phosphorus 3.8 2.7.4.5 mg/dL 3.4 01/27/2016 ALT 42 HI <41 U/L 29 01/27/2016 GGTP 19 10-71 U/L 18 01/27/2016 i :,F li I (.,...ALILLILA:' • TPT 1)-1 Cholestero 219 HI <200 L 143 01/27/2016 Triglycerides 950 HI NOTE: The result for Triglycerides has been confirmed <150 mg/dL by repeat analysis. 459 HI 01/27/2016 HOL CHOL., DIRECT 28 LO >40 mg/dL 24 LO 01/27/2016 HDL as % of Cholesterol 13 Evaluation: ABOVE AVG.(MDDERATE RISK) >14 K 17 01/27/2016 Chol/HDL Ratio 7.5 <7.4 I 6.0 101/27/2016 BioReference Laborator1e 481 Edward H. Ross Dr James meisberger, Laboratory Director Clinical Page 1 of 6 Printed 07/25/2016 07:01 abed VE91986Z12l. iPsH AsJeH WALE:GO 9102 60 6NV PROT3 BioReference LABORATORIES FINAL AWAIT D . 0 C T 0 R FISCH, HARRY HARRY FISCH. M.D. New York, NY 10028 Acct ft: C1720-1) S1 P: i olL. EPSTEIN, 0000:01/20/1953 Address:3 NEW YORK P: a) i.V tar JEFFREY Age:63 Y Sex:M I /1ST S-REET Niiiiiiii 5 Specimen ID: 105819158 A Date Of Report: 07/23/2616 M Date Collected:07/20/2616 P Date Received: 07/20/2016 L E 'Worth America Eastern Time CLINICAL REPORT .."1.4', Evaluation: ABOVE AVG.(MODERATE RISK) LOL/HOL Ratio Can't Calc <3.56 Can't Calc 101/27/2016 LDL Cholesterol Can't Calc NOTE: Unable to calculate LOL due to a Triglyceride <100 mg/(11 j Can't Calc evel of greater than 400 mg/dl. 01/27/2016 VLDL, CALCULATED Can't Celt 7-32 mg/dl I Can't talc 01/27/2016 Can't Calc: One or more components was outside the measurable range. we are unable to calculate. liEFIA1()LIDIGY .aintigitisiglinolki +r WBC 7.79 3.66-11.99 x10 3)/ul. 7.12 01/27/2016 RBC 5.18 4.20-5.90 x10(6)/ul. 4.96 01/27/2016 HGET 15.4 12.3-17.0 gm/d1 14.3 01/27/2016 HCT 43.8 39.3-52.5 41.3 01/27/2016 MCV 84.6 88.8-100.0 fL 83.3 01/27/2016 MCH 29.7 25.0-14.1 pg 28.8 01/27/2016 MCHC 35.2 MI 29.0-35.0 gm/dL 34.6 01/27/2016 ROW 14.8 10.9-16.9 13.9 01/27/2016 POLYS 45.8 36.0-78.0 49.2 01/27/2016 LYMPHS 39.0 12.0-48.0 X 36.2 01/27/2016 MONOS 8.9 0.0-13.0 7.6 01/27/2016 EOS 5.4 0.0-8.0 6.5 01/27/2016 BASOS 0.6 0.0-2.0 0.4 01/27/2016 IMMATURE GRANULOCYTES 0.0 0.0.1.6 K 0.1 61/27/2016 PLATELET COUNT 281 144-480 x10(3)/UL 222 01/27/2016 MPV 8.9 NOTE: New reference ranges for WIC and Absolute courts 8.2-11.9 fL are effective 4/25/2016. 9.5 01/27/2016 PT ThIP Test Not Performed: Specimen RE3ECTED for testing du! 9.1-11.9 sec 10.1 01/27/2016 to GROSS LIPEMIA. INTR.KORm.RATIO(INR) TAP 2.00-3.00 0.97 (0 01/27/2016 PTT TAP 23.6-31.6 sec 26.5 01/27/2016 tV1141'LYSIS 4 4. P..."' ea 1 " tai "V. Co or YELLOW YELLOW, STRAW, AMBER Character CLEAR CLEAR Specific Gravity Ur 1.025 1.003 - 1.030 pH Urine 6.5 5.0 - 8.0 Protein, Urine NEGATIVE NEGATIVE Glucose, Urine NEGATIVE NEGATIVE Ketone, Urine NEGATIVE NEGATIVE urobilinogen Urine 0.2 0.2 - 1.0 mg/dL sioReference Laboratorie 481 Edward H. Ross Dr lames Weisberger, M.D. Clinical Page 2 of 6 Printed 07/25/2016 07:01 e:?c 4£914396ZIZI. 4:GIAGBH 14:18E:SO 910? 60 Ent/ PROT4 Bi Reference LABORATORIES FINAL REPORT D OISCH, HARRY c HARRY FISCH M.D. C T New York, NY 10028 ct m 0 Ac i: iliii1) SI P: R EPSTEIN, D08:01/20/1953 Address:3 S NEW YOE, P: (N) 3EFFREY Age:63 Y Sex:M E 7151 STREET NY 10021 s Specimen ID: 105819158 A Date Of Report: 07/23/2016 ILI Date Collected: 07/20/2016 P Date Received: 07/20/2016 i North America Eastern Tine CLINICAL REPORT ::•27.4.17:::StrL ,t::;t:::,:-:: 8111rubin, Urine NEGATIVE NEGATIVE Blood, Urine NEGATIVE NEGATIVE Nitrites Urine NEGATIVE NEGATIVE Leukocyte Esterase NEGATIVE NEGATIVE Crystals Urine NONE NONE Crystal Mt. Urine NONE NONE NBC, Urine 0-4 0-4 PER HPF RBC, Urine NONE SEEN NONE SEEN PER HPF Epithelial Cells, Ur NONE FEW Cast, Hyaline, Urine 0-4 0-4 PER LPF Cast, Granular, Ur NONE SEEN 0-1 PER LPF Cast, RBC, Urine NONE SEEN 0-1 PER LPF Bacteria, Urine NONE FEW I:TCf211,1(' ( ( ' , IM,', -...,,y1a: it.'',.";:v, `;.'' riirS:'11"'' ' ' '''''`''rql, ,-,;:''._;_-..- .. r"(' ',7"tr:- ft,Fil I•401-'"."-/L.-4,.:"?'''''.. ,- .:,4"" CULTURE, URINE NO GROWTH SITE: URINE niscuLANious --..i.v,.7+.1 a:,:.. 3:i. Hemoglobin Alc 5.9 HI HEMOGLOBIN A1c ADD eAG REFERENCE RANGES Alc(%) DIABETES CATEGORY' <5.7 Normal (no 5.7-6.4 Increased ->6.5 Consistent Alt(S) eAG(ESTIFIATED AV 6 126 7 154 8 183 9 212 10 240 11 269 12 298 'recomended ranges-American Diabetes NOTE: Hemolysis, rare hemoglobin variants and thalas NJ GROWT-i gil.#. ,:::::: . ..:;:i3Zikiii.Riniar:::..itietnveii44: <5.7 6.0 Hf 1/27/2016 -diabetic) risk of diabetes with diabetes RAGE PLASMA GLUCOSE)(sg/dL) Association(2010) aria najor may affect glycemic results. TSH TNP Test Not Performed: Specimen rejected for testing due hemolysis. 0.178-4.530 uIU/mL I 1.790 101/27/2016 to moderate or marked Thyroxine(74) TNP Test Mt Performed: Specimen rejected for testing due 4.9.12.9 ug/dL I 6.3 101/27/2016 BioRefe-ence Laboratorie 481 Edward H. Ross Dr James Weisberger, M.D. Clinical Page 3 of 6 Printed 07/25/2016 07:01 g OE9P396ZLZ1 1PsN kueH 14:16E:SO 9102 60 Ent/ PROT5 HoReference LABORATORIES FINAL REPORT D 0 C T 0 R tISCH, HARRY HARRY FISCH. M.D. New York, NY 10028 Acct 41: CI720-1) Si 0: EPSTEIN, D06:01/20/1953 .Address:9 v NEW YORK .P: (S Date 3EFFREY Specimen ID: 105819158 - N Age:63 Y Sex:M Date Of Report: 07/23/2016 E 71ST STREET Date Collected: 07/20/2016 NY 10021 Received: 07/20/2816 North America Eastern Time ,/ CLINICAL Kest T3 Uptake(T3U) Test REPORT hemolysis. TNP Not Performed: Specimen rejected for testing du( hemolysis. 24.3.39.0 29.3 101/27/2016 THYROXINE, FREE(FT4) TNP Test Not Performed: Specimen rejected for testing due hemolysis. 0.80-1.73 ng/dL 0.93 101/27/2016 FREE T4 INDEX TNP 1.5-3.8 1.8 01/27/2016 T3(THYRONINE), TOTAL TNP Test Not Performed: Specimen rejected for testing due hemolysis. 72-180 ng/dl. 127 01/27/2016 PSA Total TNP Test Not Performed: Specimen rejected for testing Out hemolysis. NOTE: The PSA assay should not be the only test used Additional evaluation using DRE, ultrasound, TUR be used for this purpose. Predictions of disease based solely upon values obtained from serial PSA Patient. NOTE: Values obtained with different assay methods or used interchangeably. NOTE: Results cannot be interpreted as absolute evidence absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay <4.00 ng/mt for diagnostic purposes. or similar procedures may recurrence should not be values obtained on the kits cannot be of the presence or (Roche Diagnostics) I 0.70 101/27/2016 PSA, FREE TNP Test Not Performed: Specimen rejected for testing due hemolysis. NOTE: Results cannot be interpreted as absolute evidence presence or absence of malignant disease. Values with different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). Not Estab. ng/mL of the obtained used I 0.33 ¶01/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate cancer for men with non age group, using PSA values between 4.000 and 10.000 values is summarized in the table below: See Below -suspicious DRE results, by ng/ml. and percent FREE PSA I 47 101/27/2016 81oReference Laboratorie 481 Edward H. Ross Dr James Weisberger, M.D. Clinical Page 4 of 6 Printed 07/25/2016 07:01 L abed P£91.886Z Llasid AIRH Wd0tt:S0 9L0Z 60 End PROT6 BioReference LABORATORIES FINAL REPORT u FISCH, HARRY J HARRY ;ISCH H.D. New 'for*, NY 10028 'f siEW Acct n: C1720-1) Si R y;, ;'. EPSTEIN, DOB:01/2 Anddress: • YORK ( JEFFREY ;1953 Age:63 Y Sex:M F 715T STRICT NV 10021 5 A v P r Specimen ID: 105819158 Date Of Report: 07/23/2016 Date Collected: 07/20/2816 Date Received: 07/20/2016 North America Eastern Time PROBABILITY OF CANCER' %free P5A (59-59 yrs) (60-69 yrs) <orate 49.2% 57.5% 11-18 26.9% 33.9% 19-25 18.3% 23.9% >25 9.1% 12.2% 'probability of finding prostate cancer by need NOTE: Calculation of percent FREE PSA may not be pos TOTAL PSA is in the low normal range. These gu performed using the Roche E6192 immunoassay sys e_ (>orp yrs) 64.5% 40.8% 29.7% 15.8% e biopsy ible when the value for elines are for assays m.(8/2015:1/8.6) TESTOSTERONE, TOT.,5. TIP Test hot Performed: Specimen rejected for testing du hemolysis. 193.0-740.0 ng/dL 296.8 101/27/2916 TESTOSTERONE, BIOAVAIL. TNP 72.B-468.0 n dl 183.8 01/27/2816 SEX HORM.BIND.GLOB. TNP Test Not Performed: Specimen rejected for testing du hemolysis. 18-57 nmol/L 18 1 27 016 FREE TESTOSTERONE TNP 30.09.156.88 pg/mL 88.18 81/27/2016 LH TNP Test Not Performed: Specimen rejected for testing du hemolysis. 1.7.8.6 mIll/mL 6.8 81/27/2016 FSH TNP Test Not Performed: Specimen rejected for testing du hemolysis. 1.5-12.4 mIlt/ml. j 6.8 181/27/2816 PROLACT111, SERUM TNP Test Net Performed: Specimen rejected for testing du hemolysis. 4.0-15.2 ng/mL 3.0 LO 181/27/2016 ESTRADIOL TNP Test Not Performed: Specimen rejected for testing duhemolysis. 7.02-49.06 p8/mL J 48.93 101/27/2816 FIBRINOGEN TNP 176-441 mg/OL I 276 01/27/2816 DIHYDROTESTOSTERONE(7) 148.0 Reference Intervals for Males age 20 years and abov : 106.0-719.0 pg/aL Analysis by High Performance Liquid Chromatography/ TandemMass Spectrometry (LC-M5/MS) 106-719 pg/mt. I 278.0 01/27/2616 (7) Performed by: National Medical Lab 2300 Stratford Ave. Willow Grove, PA 19090 BioReference Laborator 481 Edward H. ROSS or 1111~1 lases Weisberger, N.D. Clinical Page 5 of 6 Printed 07/25/2016 87:01 8 abed P£91.896Z2L AMEH Wd04:90 9102 60 6nV PROT7